Real-world Data in Patients With Breast Cancer Treated With Abemaciclib

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885 ·Status: TERMINATED ·Phase: PHASE4

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

NCT02779751 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

NCT04707196 ·Status: COMPLETED ·Phase: PHASE4

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

NCT06344780 ·Status: ACTIVE_NOT_RECRUITING

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481 ·Status: COMPLETED

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508 ·Status: TERMINATED ·Phase: PHASE2

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

NCT07292207 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer

NCT04071262 ·Status: COMPLETED ·Phase: PHASE1

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

NCT04732598 ·Status: COMPLETED ·Phase: PHASE3

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

NCT07180693 ·Status: RECRUITING

Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

NCT06341621 ·Status: RECRUITING ·Phase: PHASE3

Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

NCT06500208 ·Status: RECRUITING ·Phase: PHASE2

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

NCT03356860 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

NCT06908668 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

NCT01394016 ·Status: COMPLETED ·Phase: PHASE1

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

NCT06075758 ·Status: COMPLETED

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

NCT05677308 ·Status: COMPLETED

Dalpiciclib in HR+/HER2- ABC

NCT06301438 ·Status: RECRUITING

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

NCT05155566 ·Status: COMPLETED

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

NCT04075604 ·Status: COMPLETED ·Phase: PHASE2

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

NCT04767594 ·Status: ACTIVE_NOT_RECRUITING